39th week of 2011 patent applcation highlights part 56 |
Patent application number | Title | Published |
20110237479 | Method of Lubricating an Internal Combustion Engine - The invention provides a method of lubricating an internal combustion engine in the presence of a contaminant amount of water. The invention further relates to the use of a derivative of a hydroxy-carboxylic acid or a monoester of a polyol and an aliphatic carboxylic acid as a rust inhibitor. | 2011-09-29 |
20110237480 | CLEANING COMPOSITION, CLEANING PROCESS, AND PROCESS FOR PRODUCING SEMICONDUCTOR DEVICE - A cleaning method is provided that includes a step of preparing a cleaning composition containing 57 to 95 wt % of (component a) water, 1 to 40 wt % of (component b) a secondary hydroxy group- and/or tertiary hydroxy group-containing hydroxy compound, (component c) an organic acid, and (component d) a quaternary ammonium compound, the composition having a pH of 5 to 10, and a step of removing plasma etching residue formed above a semiconductor substrate by means of the cleaning composition. There are also provided a process for producing a semiconductor device that includes a step of cleaning plasma etching residue formed above a semiconductor substrate using the cleaning method, and a cleaning composition for removing plasma etching residue formed above a semiconductor substrate that contains 57 to 95 wt % of (component a) water, 1 to 40 wt % of (component b) a secondary hydroxy group- and/or tertiary hydroxy group-containing hydroxy compound, (component c) an organic acid, and (component d) a quaternary ammonium compound, the composition having a pH of 5 to 10. | 2011-09-29 |
20110237481 | THICKENED OVEN CLEANER, ASSOCIATED CLEANERS, AND ASSOCIATED METHODS - Cleaner compositions, associated cleaners, and associated methods are disclosed. The cleaner compositions are capable for use in making thickened cleaners that are capable of removing from vertical and inverted surfaces fresh, greasy soils and baked-on soils encountered in the food service industry. The cleaner compositions include one or more alkalinity sources, one or more chelants, one or more surfactants, one or more thickening agents, one or more buffers, and as a remainder, water. Cleaner compositions of the invention are substantially free of phosphates and have a low caustic content making them user and environmentally friendly. Yet the cleaners of the invention are surprisingly effective at removing tenacious baked-on soils encountered in the food service industry. Compositions of the invention have a viscosity of about 700 cps and are applied using a foaming or misting dispenser. The one or more alkalinity sources may be present in an amount sufficient to provide a free alkalinity (expressible as Na | 2011-09-29 |
20110237482 | DISHWASHER DETERGENT - Phosphate-free, bleach-free automatic dishwashing agents comprising 10 to 60 wt % citrate and from 1 to 30 wt % maleic acid are described, wherein the automatic dishwashing agents are characterized by good cleaning performance, particularly in the improved cleaning of tea stains. | 2011-09-29 |
20110237483 | CLEANING AGENT FOR HIGH VISCOSITY METALWORKING FLUID - The present invention relates to a agent for cleaning metal drawing oil, which contains alcohol, glycol ether, water, and one or more compounds selected from hydrocarbon or ester compounds. The cleaning agent according to the present invention is environmentally friendly because it does not contain halogen elements such as chlorine. The agent can reduce toxicity on the human body due to low volatility; is economical due to the long change period resulting from the reduction of evaporation; and removes drawing oil having high viscosity and polarity effectively during metal processing. | 2011-09-29 |
20110237484 | ELECTROCHEMICAL TEXTILE-WASHING PROCESS - The present invention relates to a washing machine comprising an electrochemical cell, to a process for electrochemical cleaning of fibers, to laundry detergents for electrochemical cleaning of fibers and to the fibers thus cleaned. | 2011-09-29 |
20110237485 | Chrysosporium Cellulase and Methods of Use - The subject invention relates to novel compositions of neutral and/or alkaline cellulase and methods for obtaining neutral and/or alkaline cellulase compositions from | 2011-09-29 |
20110237486 | LIQUID LAUNDRY DETERGENT COMPOSITIONS WITH MODIFIED POLYETHYLENEIMINE POLYMERS AND LIPASE ENZYME - A liquid laundry detergent for improved grease and oil cleaning having a lipase enzyme, a modified polyethyleneimine polymer and a liquid carrier. | 2011-09-29 |
20110237487 | FABRIC AND HOME CARE PRODUCTS - This invention relates to fabric and home care products comprising one or more cold water proteases and processes for making and using such products. Such compositions provide improved cleaning and freshness. Such cold water proteases may be derived from parent enzymes, including BPN′ subtilisin and subtilisin derived from | 2011-09-29 |
20110237488 | SOLVENT COMPOSITIONS COMPRISING UNSATURATED FLUORINATED HYDROCARBONS - This invention relates to cleaning compositions comprising unsaturated fluorinated hydrocarbons. The invention further relates to use of said cleaning compositions in methods to clean, degrease, deflux, dewater, and deposit fluorolubricant. The invention further relates to novel unsaturated fluorinated hydrocarbons and their use as cleaning compositions and in the methods listed above. | 2011-09-29 |
20110237489 | METHODS OF MAKING FABRIC SOFTENER - Optimizing water conductivity, water temperature, and fabric softener active percentage when making a concentrated fabric softener active hydrate yields fabric softener products of desired rheology and stability. | 2011-09-29 |
20110237490 | METHODS OF MAKING FABRIC SOFTENER - Optimizing dilution processing, include the use of cold dilution water, yields fabric softener products of desired rheology and stability. | 2011-09-29 |
20110237491 | Multiple Use Fabric Conditioning Block With Indentations - Multiple use fabric conditioning blocks comprising indentations and/or protrusions are useful for conditioning fabric. | 2011-09-29 |
20110237492 | TREATMENT OF DISEASES AND CONDITIONS MEDIATED BY INCREASED PHOSPHORYLATION - The invention provides methods for the treatment of diseases and conditions mediated by increased phosphorylation, such as inflammation and cancer. The invention also provides methods for the inhibition of increased phosphorylation in cells, tissues and organs. The methods utilize a phosphate acceptor compound (PAC). The invention also provides products comprising a PAC. | 2011-09-29 |
20110237493 | DIPEPTIDE LINKED MEDICINAL AGENTS - A non-enzymatically self cleaving dipeptide element is provided that can be linked to known medicinal agents via an amide bond. The dipeptide will spontaneously be cleaved from the medicinal agent under physiological conditions through a reaction driven by chemical instability. Accordingly, the dipeptide element provides a means of linking various compounds to known medicinal agents wherein the compounds are subsequently released from the medicinal agent after a predetermined time of exposure to physiological conditions. For example, the dipeptide can be linked to an active site of a drug to form a prodrug and/or the dipeptide may comprise a depot polymer to sequester an injectable composition comprising the complex at the point of administration. | 2011-09-29 |
20110237494 | USE OF PEPTIDIC VASOPRESSION RECEPTOR AGONISTS - The present invention relates to the use of novel compounds for the manufacture of a medicament for treatment of inter alia conditions associated with critical care as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds utilised are represented by the general formula (I), as further defined in the specification. | 2011-09-29 |
20110237495 | FUNCTIONAL METABOLOMICS COUPLED MICROFLUIDIC CHEMOTAXIS DEVICE AND IDENTIFICATION OF NOVEL CELL MEDIATORS - The invention relates to the use of microfluidic chemotaxis device to identify novel active compounds of the metabolome and methods to characterize their actions on cell motility. The invention also includes the active compounds of the metabolome identified by the methods and devices disclosed herein. The results from these in vitro experiments were then correlated with in vivo physiologic responses to identify the downstream effects and therapeutic value. Thus, the invention provides novel methods for treating or preventing second organ injury resulting from ischemia-reperfusion in a patient in need thereof The invention also provides methods of treating, preventing or ameliorating connective tissue degeneration in a patient in need thereof. The invention also provides methods of treating or preventing bone loss. In addition, the invention provides method for inducing bone regeneration in patients in need thereof or preventing bone loss in patients suspected to be in need thereof. | 2011-09-29 |
20110237496 | ANTINECROTIC ACTIVITY OF ALPHA 1-ANTITRYPSIN - The present invention is related to the use of alpha-1-antitrypsin as an anti-necrotic agent. This invention provides a method for the treatment of tissue necrosis by administration of alpha-1-antitrypsin. This invention further provides methods for prophylactic treatment of tissue necrosis and for inhibition of tissue necrosis in culture by addition of alpha-1-antitrypsin. | 2011-09-29 |
20110237497 | COMPOSITIONS OF A V-ATPASE INHIBITOR IN COMBINATION WITH A GLUCOCORTICOID RECEPTOR LIGAND AND METHODS OF USE - A composition of a glucocorticoid receptor (GR) ligand, or analog thereof, and a V-ATPase inhibitor, or analog thereof. A method for administering such composition to a cell either to increase glucocorticoid transrepression activity or to increase glucocorticoid transactivation activity in the cell. Also, a method for treating a subject having an inflammatory or auto-immune disease by administering such composition. | 2011-09-29 |
20110237498 | SOLUBLE POLYPEPTIDES FOR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS - The present invention relates to soluble CD47 binding polypeptides, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble CD47 binding polypeptide for use as a medicament, comprising an extracellular domain of SIRPα (CD172a) or functional derivatives which bind to human CD47. | 2011-09-29 |
20110237499 | HYBRID TRIPYRROLE-OCTAARGININE COMPOUNDS AND THEIR USE AS MEDICAMENT IN THE TREATMENT OF CANCER AND MICROBIAL ILLNESSES - Hybrid tripyrrole-octaarginine compounds. Hybrids formed by a tripyrrole group bound to a polyarginine peptide which permit the efficient cellular internalization and promote a greater affinity for the DNA. The method of obtainment and uses thereof. | 2011-09-29 |
20110237500 | CECROPIN-MAGAININ HYBRID PEPTIDES - The present invention relates to a biocidal fusion peptide of SEQ ID NO: 1 or a sequence with at least 90% identity thereto, compositions such as pharmaceutical compositions comprising the same, methods of preparing the peptide, and use of the peptide in treatment, in particular for the treatment of bacterial infection and/or fungal infection and/or viral infection. | 2011-09-29 |
20110237501 | Detection of Mutations in a Gene Associated with Resistance to Viral Infection, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided. | 2011-09-29 |
20110237502 | Insecticidal Polypeptides and Methods of Use Thereof - A family of insecticidal polypeptides expressed in the venom gland of spiders of the genera | 2011-09-29 |
20110237503 | NOVEL PEPTIDES AND METHODS FOR THEIR PREPARATION AND USE - The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R. | 2011-09-29 |
20110237504 | DELIVERY AGENTS FOR ENHANCING MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS - A delivery agent for delivering a biologically active agent to a warm-blooded animal includes a hydrophobic moiety covalently bonded to a hydrophilic moiety. The hydrophobic moiety can include bile acids, sterols, or hydrophobic small molecules. The hydrophilic moiety can include α-amino acids, dipeptides or tripeptides, or hydrophilic small molecules. An illustrative delivery agent is N | 2011-09-29 |
20110237505 | Compositions and Methods for Treating Obesity and Diabetes - Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal. | 2011-09-29 |
20110237506 | PROTEIN STABILIZATION FORMULATIONS - The present invention is directed to stabilizing Bone Morphogenetic Protein in various lyophilized formulations and compositions. The present invention comprises formulations primarily including trehalose as an excipient for lyophilized compositions and their subsequent storage and reconstitution, and can also optionally include other excipients, including buffers and surfactants. | 2011-09-29 |
20110237507 | METHODS OF PROTECTING AGAINST APOPTOSIS USING LIPOPEPTIDES - The use of lipopeptides as inducers of NF-κB for the protection of mammals from the effects of apoptosis is described. | 2011-09-29 |
20110237508 | Peptide Formulations and Uses Thereof - The present invention relates to the field of preventive and therapeutic medicine, in particular to peptide formulations. Provided is a pH-buffered aqueous formulation comprising oxytocin, vasopressin or an analogue thereof and at least one non-toxic source of divalent metal ions in a concentration of at least 2 mM, and the use of the formulation for the manufacture of a medicament for therapeutic and/or prophylactic treatments. Also provided is a method for treating or preventing haemorrhage in a subject in need thereof, comprising administering to said subject an effective dosage amount of an oxytocin formulation according to the invention. Further provided is a method for treating or preventing diabetes insipidus or vasodilatory shock in a subject in need thereof, comprising administering to said subject an effective dosage amount of a vasopressin formulation according to the invention. | 2011-09-29 |
20110237509 | hGH AND METHODS FOR PREPARING hGH - Preparations of recombinant human growth hormone (hGH) are provided having a purity that comprises 2% or less of a peptide other than native human growth hormone (e.g., essentially free of multimeric forms) are disclosed. Active pharmaceutical ingredient (API) preparations of recombinant hGH suitable for commercial production of formulation grade recombinant hGH are provided. A stable Master Cell Bank of transformed | 2011-09-29 |
20110237510 | STABILIZED GLUCAGON SOLUTIONS - A formulation composed of a sugar such as glucose and a surfactant such as myristoyl lysophosphocholine (LMPC) has been designed to stabilize both hydrophilic and hydrophobic portions of the glucagon molecule, under prolonged physiological conditions, in a formulation that is sufficiently similar to the pH and osmolarity of plasma so as not to induce or to minimize site irritation. The combination of a simple sugar and an surfactant stabilizes the glucagon molecule in an aqueous solution for seven days at 37° C. | 2011-09-29 |
20110237511 | EP4 Receptor Agonist, Compositions and Methods Thereof - This invention relates to potent selective agonists of the EP | 2011-09-29 |
20110237512 | Methods for Treating Bleeding Disorders Using Sulfated Polysaccharides - Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described. | 2011-09-29 |
20110237513 | LTBP2 AS A BIOMARKER FOR RENAL DYSFUNCTION - The application discloses LTBP2 as a new biomarker for renal dysfunction; methods for predicting, diagnosing, prognosticating and/or monitoring said dysfunction based on measuring said biomarker; and kits and devices for measuring said biomarker and/or performing said methods. | 2011-09-29 |
20110237514 | PHARMACEUTICAL COMPOSITION FOR TREATING BONE DISEASES WHICH COMPRISES PROTEIN COMPRISING Frizzled1, Frizzled2 OR Frizzled7 EXTRACELLULAR CYSTEINE-RICH DOMAIN - This invention relates to a pharmaceutical composition for treatment of a bone disease comprising, as an active ingredient, a protein comprising an extracellular cysteine-rich domain, which is from the Frizzled receptor selected from the group consisting of mammalian animal-derived Frizzled 1, Frizzled 2, and Frizzled 7 and has activity of increasing bone mass, bone density, and/or bone strength, or a mutant of such domain having sequence identity of 85% or higher to the amino acid sequence of the domain and having activity of increasing bone mass, bone density, and/or bone strength, or a vector comprising a nucleic acid encoding the protein. | 2011-09-29 |
20110237515 | PEPTIDE DERIVED FROM NEUROTESIN RECEPTOR 3 AND USE THEREOF IN THE TREATMENT OF PSYCHIATRIC DISEASES - The invention relates to a peptide derived from neurotensin receptor 3 (NTSR3), and to the use thereof in the treatment of psychiatric diseases. The present invention particularly relates to the use of this peptide for producing a drug, such as an antidepressant. The peptide of the invention is characterized in that the sequence thereof is the attached SEQ ID No. 2. The present invention can be used in the fields of the pharmaceutical industry and particularly in the field of drug development for treating psychiatric diseases. The present invention can also be used in the development of a novel antidepressant. It can also be used for example, in the treatment of pain and inflammations. | 2011-09-29 |
20110237516 | PLANT-DERIVED ELASTIN BINDING PROTEIN LIGANDS AND METHODS OF USING THE SAME - The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents. | 2011-09-29 |
20110237517 | IAP INHIBITORS - The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. | 2011-09-29 |
20110237518 | METHOD FOR TREATING OR PREVENTING BLADDER CANCER USING THE DEPDC1 POLYPEPTIDE - The present invention provides therapeutic agents and methods for treating cancer using the polypeptides posed of an amino acid sequence which includes a polypeptide fragment of DEPDC1. The polypeptides of the present invention can be introduced into cancer cells by modifying the polypeptides with transfection agents such as poly-arginine. Furthermore, the present invention provides methods of screening for therapeutic agents or compounds useful in inhibition of the DEPDC1/ZN-F224 complex formation or the treatment of cancer. The present invention also provides siRNAs targeting the ZNF224 gene, which are suggested to be useful in the treatment of bladder cancer. | 2011-09-29 |
20110237519 | Hematopoietic Growth Factor Inducible Neurokinin-1 Gene and Uses Thereof - The present invention discloses the cloning of a new cDNA, HGFIN, from stimulated bone marrow stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The novel gene, HGFIN, encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. HGFIN is implicated in the treatment of hyperproliferative disorders, particularly bone and breast cancer, because it acts to suppress the proliferating cells. | 2011-09-29 |
20110237520 | Anticancer Compounds - Compounds of general formula I: | 2011-09-29 |
20110237521 | SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE - Methods and compositions are disclosed for controlling expression of TNF receptors (TNFR1 and TNFR2) and of other receptors in the TNFR superfamily using compounds that modulate splicing of pre-mRNA encoding these receptors. More specifically these compounds cause the removal of the transmembrane domains of these receptors and produce soluble forms of the receptor which act as an antagonist to reduce TNF-α activity or activity of the relevant ligand. Reducing TNF-α activity provides a method of treating or ameliorating inflammatory diseases or conditions associated with TNF-α activity. Similarly, diseases associated with other ligands can be treated in like manner. In particular, the compounds of the invention are splice-splice switching oligomers (SSOs) which are small molecules that are stable in vivo, hybridize to the RNA in a sequence specific manner and, in conjunction with their target, are not degraded by RNAse H. | 2011-09-29 |
20110237522 | NEUTRAL NANOTRANSPORTERS - Neutral lipid formulations for nucleic acid delivery are provided according to the invention. The neutral lipid formulations include hydrophobically modified polynucleotides and fat mixtures. Methods of using the neutral lipid formulations are also provided. | 2011-09-29 |
20110237523 | CONTRACEPTIVE PEPTIDES DERIVED FROM THE VENOM OF THE SPIDER Latrodectus mirabilis, NUCLEOTIDE SEQUENCES TO TRANSFORM A MICROORGANISM TO PRODUCE SAID PEPTIDES; METHODS TO OBTAIN THE PEPTIDES; PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF AND USE THEREOF - The present invention is directed to an active agent with contraceptive properties. Said active agent corresponds to a molecular fraction of the venom from the spider | 2011-09-29 |
20110237524 | POLYMER CONJUGATES OF AOD-LIKE PEPTIDES - The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer. | 2011-09-29 |
20110237525 | METHOD OF AMELIORATING OXIDATIVE STRESS AND SUPPLEMENTING THE DIET - A method of supplementing a diet and ameliorating oxidative stress in a mammal includes administering a pharmaceutically effective amount of lipid soluble, hydrophobic active compounds having a chemical structure: | 2011-09-29 |
20110237526 | METHOD FOR THE PREPARATION OF A CRYSTALLINE FORM - The invention relates to a method for the preparation for a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene. In addition the invention relates to a crystalline form obtainable by this method, to a pharmaceutical composition and to the use thereof for preparing medicaments. | 2011-09-29 |
20110237527 | SGLT-2 INHIBITORS, METHODS OF MAKING THEM, AND USES THEREOF - The present invention relates to compounds which are inhibitors of sodium dependent glucose co-transporter-2 (SGLT-2). These compounds are used in the treatment of various disorders, including diabetes, impaired glucose tolerance, insulin resistance, retinopathy, nephropathy, neuropathy, cataracts, hyperglycemia, hyperinsulinemia, hyperchlolesterolemia, elevated blood level of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis, and hypertension. These compounds and compositions are also useful for treating and preventing kidney stones, hyperuricemia, gout, and hyponatremia. Methods of making these compounds are also described in the present invention. | 2011-09-29 |
20110237528 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES - The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-3 or encompassed by formulas (I), (IA), (IB), (II), and (III)) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease. | 2011-09-29 |
20110237529 | Adenosine Analogs and Their Use - The invention provides adenosine analog compounds that act at P2Y receptors, e.g., the P2Y | 2011-09-29 |
20110237530 | ANTI-XDR-TB DRUG, ANTI-MDR-TB DRUG, AND COMBINATION ANTI-TUBERCULOSIS DRUG - A method for treating an individual infected with XDR-TB, the method including administering to the individual an anti-XDR-TB drug which comprises a compound having a structure expressed by Structural Formula (1) below: | 2011-09-29 |
20110237531 | METHOD FOR PRODUCING SOPHOROSE LIPID - The present invention provides a low-cost, efficient method for producing a glycolipid biosurfactant, in particular, lactonic sophorose lipids. This method is characterized by culturing a microorganism capable of producing the biosurfactant under limited oxygen supply. The present invention enables preferential production of lactonic sophorose lipids and facilitates recovery of the lactonic sophorose lipids in a solid form. Further, the present invention enables production of high purity acidic sophorose lipids by hydrolyzing high purity lactonic sophorose lipids produced by the above method. The present invention also provides lactonic sophorose lipids that possess strong antibacterial and antifungal activities, and an antibacterial and/or antifungal agent containing the sophorose lipids. | 2011-09-29 |
20110237532 | 1-[(3-CYANO-PYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-[3-(R)-AMINO-- PIPERIDIN-1-YL]-XANTHINE FOR THE TREATMENT OF A METABOLIC DISORDER OF A PREDOMINANTLY CARNIVOROUS NON-HUMAN ANIMAL - The present invention provides a pharmaceutical composition comprising 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or a pharmaceutically acceptable form thereof as pharmaceutically active compound for the therapy of a metabolic disorder or metabolic disease of a predominantly carnivorous non-human animal. It is especially useful for the therapy of diabetes and related diseases of predominantly carnivorous mammals like cats or dogs. The invention further provides respective uses of such compositions and of 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(R)-amino-piperidin-1-yl]-xanthine or pharmaceutically acceptable forms thereof. | 2011-09-29 |
20110237533 | NOVEL POLYPHENOL COMPOUND - Compounds represented by formula (I) | 2011-09-29 |
20110237534 | METHODS FOR TREATING GASTROINTESTINAL DISEASES - Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating gastrointestinal diseases. | 2011-09-29 |
20110237535 | Use of Induced Pluripotent Cells and other Cells for Screening Compound Libraries - The invention provides methods for screening test compounds or toxins for effects on cells. The invention also provides methods for determining frequency, amplitude and kinetic profiles of cells. | 2011-09-29 |
20110237536 | Treating or Preventing Pain Using Spicamycin Derivatives - The present invention relates to the use of spicamycin derivatives for treatment and/or prevention of pain, including neuropathic pain. The invention further relates to pharmaceutical compositions of spicamycin derivatives suitable for treatment or prevention of pain. | 2011-09-29 |
20110237537 | METHODS FOR ASSESSMENT AND TREATMENT OF MOOD DISORDERS VIA SINGLE NUCLEOTIDE POLYMORPHISMS ANALYSIS - Described herein are assays, kits and methods for treating mood disorders by testing for one or more polymorphisms in a specific group of genes and for analyzing the results of polymorphism testing; the genes included may converge in one or more signaling pathways, and may be epigenetic. The genes are included based on the relationships of the proteins encoded by the genes in the context of particular signaling pathways and provide a diagnostically relevant nexus. Also described herein are methods of presenting the data collected by the screen, including methods of delivering interpretive comments and/or treatment guidance based on the results of the genetic screening either individually or based on the genetic composition of particular clusters of genes which may be related to each other. Importantly, drugs which modulate these genetic disturbances are described for targeted therapeutic use based upon companion diagnostic method. | 2011-09-29 |
20110237538 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES - Described are various compounds, in particular iminosugars, and methods for the treatment of proteostatic diseases, in particular lysosomal storage disorders. The compound may be a pharmacoperone of an enzyme selected from: (a) Acid alpha-glucosidase; (b) Acid beta-glucosidase; (c) glucocerebrosidase; (d) alpha-Galactosidase A; (e) Acid beta-galactosidase; (f) beta-Hexosaminidase A; (g) beta-Hexosaminidase B; (h) Acid sphingomyelinase; (i) Galactocerebrosidase; (j) Acid ceramidase; (k) Arylsulfatase A; (l) alpha-L-Iduronidase; (m) Iduronate-2-sulfatase; (n) Heparan N-sulfatase; (o) alpha-N-Acetylglucosaminidase; (p) Acetyl-CoA: alpha-glucosaminide N-acetyltransferase; (q) N-Acetylglucosamine-6-sulfate sulfatase; (r) N-Acetylgalactosamine-6-sulfate sulfatase; (s) Acid beta-galactosidase; (t) Arylsulfatase B; (u) beta-Glucuronidase; (v) Acid alpha-mannosidase; (w) Acid beta-mannosidase; (x) Acid alpha-L-fucosidase; (y) Sialidase; and (z) alpha-N-acetylgalactosaminidase. | 2011-09-29 |
20110237539 | Spinning Solution and Method for Manufacturing Biomaterial Fibers - Disclosed herein are spinning solutions and methods for manufacturing a biomaterial fiber. The spinning solution includes a biologically absorbable material having a haemostatic function, a polysaccharide selected from the group consisting of hyaluronic acid (HA) and gelatin, and a solvent, wherein the polysaccharide and the haemostatic material exist in a weight ratio between about 0.1 to about 3. The method includes steps of wet spinning the spinning solution into the biomaterial fiber. | 2011-09-29 |
20110237540 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY - Methods and compositions relating to CDP-taxane conjugates are described herein. | 2011-09-29 |
20110237541 | TRANSDERMALLY ADMINISTERED ALISKIREN - Dosage form of aliskiren, comprising a device for transdermal administration of aliskiren and aliskiren (including salts, prodrugs and metabolites thereof), optionally together with pharmaceutically acceptable carrier(s) to a human being or an animal in order to achieve a desired therapeutic effect. Use of a compound comprising aliskiren, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s), for the manufacture of a composition to be administered transdermally for achieving a desired therapeutic effect. Method for achieving a desired therapeutic effect by transdermal administration of a compound comprising aliskiren, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s). | 2011-09-29 |
20110237542 | COMPOSITION FOR PREVENTING ADHESION - The present invention relates to a composition for preventing tissue adhesion which comprising a bio-compatible hyaluronic acid and a polymer compound. More specifically, the invention is a composition containing hyaluronic acid which has not been modified by a chemical crosslinking or other chemical modification a method for preparing the same, and a composition for adhesion prevention with superior efficacy. | 2011-09-29 |
20110237543 | Composition for Prevention or Treatment of Eye Diseases - Provided is a composition for prophylaxis or treatment of an eye disease comprising a compound represented by General Formula I: | 2011-09-29 |
20110237544 | Novel Pharmaceutical Agents Containing Carbohydrate Moieties And Methods Of Their Preparation And Use - Hydrophilic N-linked pharmaceutical compositions, methods of their preparation and use in neuraxial drug delivery comprising a glycosyl CNS acting prodrug compound covalently N-linked with a saccharide through an amide or an amine bond and a formulary consisting of an additive, a stabilizer, a carrier, a binder, a buffer, an excipient, an emollient, a disintegrant, a lubricating agent, an antimicrobial agent or a preservative, with the proviso that the saccharide moiety is not a cyclodextrin or a glucuronide. | 2011-09-29 |
20110237545 | TRIHYDROXY POLYUNSATURATED EICOSANOID DERIVATIVES - The invention features methods for the preparation of naturally occurring trihydroxy polyunsaturated eicosanoids and their structural analogs. The invention further provides new derivatives and analogs of trihydroxy polyunsaturated eicosanoids that can be prepared according to these methods. The invention also provides compositions and methods using trihydroxy polyunsaturated eicosanoid derivatives for the prevention, amelioration and treatment of a variety of diseases or conditions associated with inflammation or inflammatory response, autoimmune diseases, rheumatoid arthritis, cardiovascular diseases, or abnormal cell proliferation or cancer. | 2011-09-29 |
20110237546 | METHOD FOR TREATING A MAMMAL BY ADMINISTRATION OF A COMPOUND HAVING THE ABILITY TO RELEASE CO - Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin. | 2011-09-29 |
20110237547 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FUNGAL INFECTIONS - Synergistic combinations of a squalene epoxidase inhibitor and a leucyl-tRNA synthetase inhibitor are provided, which are useful in particular in the treatment of diseases involving fungal or suspected fungal infection, for immunomodulation or immunosuppression in conditions in which fungal or suspected fungal colonisation of e.g. the skin or nail plays a role, such as atopic dermatitis, acne vulgaris, seborrhoeic dermatitis, rosacea or onychomycosis, and in situations of fungal resistance. | 2011-09-29 |
20110237548 | SYNERGISTIC COMPOSITION AND METHOD OF RETARDING AND AMELIORATING PHOTO INDUCED RETINAL DAMAGE AND CATARACTS WHILE AMELIORATING DRY EYE SYNDROME USING OMEGA CHOLINE - A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from omega choline, in which said omega choline contains at least 30% total phospholipids, in a therapeutically effective amount to prevent, retard or treat eye central nervous system diseases or injuries, such as age-related macular degeneration, cataract, dry eye syndrome due to glandular inflammation and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases. | 2011-09-29 |
20110237549 | MODULATORS OF RNA RIBOSWITCHES - Provided is a computer model generated from a data array, computer readable storage media encoded with the model, and computers comprising the model, wherein the model is derived from atomic structure coordinates of a FMN riboswitch or a lysine riboswitch. Further provided is a pharmacophore having a spatial arrangement of atoms defined by the binding pocket identified in the model, along with a compound defined by the pharmacophore. Also further provided are methods for rational drug design based on the atomic structure data, and compounds identified by the rational drug design process. | 2011-09-29 |
20110237550 | 5-AZAINDOLE BISPHOSPHONATES - Novel 5-azaindole bisphosphonate compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating abnormal calcium and phosphate metabolism, including bone and joint diseases and other disorders. | 2011-09-29 |
20110237551 | Para-Coumaric Acid or Para-Hydroxycinnamic Acid Derivatives and Their Use in Cosmetic or Dermatological Compositions - The invention relates to the use of para-coumaric acid or para-hydroxycinnamic acid derivatives in cosmetic or dermatological compositions, specifically to the use of at least one compound derived from para-coumaric acid having a general formula (I) below: | 2011-09-29 |
20110237552 | Composite Material Consisting of a Collagen Matrix Mineralised with Silicate and Calcium Phosphate Phases, Method for the Production and Use Thereof - The invention relates to novel composite materials based on a collagen matrix mineralised with silicate and calcium phosphate phases, to a method for the production thereof and use thereof as an implant material which can be shaped in a plurality of ways, a biological coating or active substance carrier. The claimed composite material comprises a collagen matrix which is mineralised with silicate and a calcium phosphate phase, said collagen being a recombinate collagen, collagen from Eumetazoa, sponge collagen from a sponge of the Demospongia class (horn sponges) or Calcarea (calcareous sponges), a synthetic collage analogue, a collagen derivative or a mixture of said collagens. | 2011-09-29 |
20110237553 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 2011-09-29 |
20110237554 | Combination therapies: inhibitors of GABA transaminase and NKCC1 - Inhibitors of NKCC1, such as bumetanide, when coadministered with inhibitors of GABA transaminase, such as vigabatrin, attenuate both the retinal toxicity and the intramyelinic edema. | 2011-09-29 |
20110237555 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF ROSACEA - The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea. | 2011-09-29 |
20110237556 | (20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-HYDROXYVITAMIN D3 - Compounds of formula I are provided where X | 2011-09-29 |
20110237557 | DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1ALPHA,25-DIHYDROXYVITAMIN D3 - Compounds of formula I are provided where X | 2011-09-29 |
20110237558 | STABILIZED COMPOSITION FOR TREATING PSORIASIS - A storage stable ointment of the present invention comprises a vitamin D compound, a corticosteroid, and an N,N-di(C | 2011-09-29 |
20110237559 | 6-SUBSTITUTED SULFONYL AZABICYCLO[3.2.1]OCTANES USEFUL TO INHIBIT 11Beta-HYDROXYSTEROID DEHYDROGENASE TYPE-1 - In its many embodiments, the present invention relates to a novel class of 6-substituted sulfonyl-1,3,3-trialkyl-6-azabicyclo[3.2.1]octane compounds useful to inhibit 11β-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11β-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions. | 2011-09-29 |
20110237560 | MODULATING AND/OR DETECTING ACTIVATION INDUCED DEAMINASE AND METHODS OF USE THEREOF - A method for stratifying a subject, said method comprising: measuring the AID expression and/or activity in a first sample of the subject, and comparing said expression and/or activity to a reference AID expression and/or activity, wherein an AID expression and/or activity in the first sample of the subject that is higher than the reference AID expression and/or activity is indicative that the subject would benefit from a treatment with at least one Heat Shock Protein 90 (Hsp90) inhibitor. | 2011-09-29 |
20110237561 | ORGANIC COMPOUNDS - Optionally substituted 4,5,7,8-tetrahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine or 4,5,7,8,9-pentahydro-(optionally 4-oxo, 4-thioxo or 4-imino)-2H-pyrimido[1,2-a]pyrrolo[3,4-e]pyrimidine compounds or Compounds of Formula (I), processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising the same. | 2011-09-29 |
20110237562 | USE OF A CONTAINER OF AN INORGANIC ADDITIVE CONTAINING PLASTIC MATERIAL - The present invention relates to the use of a container, made of an inorganic additive containing plastic material, for reducing physical/chemical interaction between the container and an oil, fat and/or wax containing formulation contained therein. | 2011-09-29 |
20110237563 | FAST DISSOLVING DRUG DELIVERY SYSTEMS - The present invention related to the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with critical buccal condition, leading to difficulties in swallowing oral medicine forms and thus difficulties in treating said illnesses. Particularly, the present invention discloses the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for treating illnesses of patient with dysphagia and/or odynophagia and/or aspiration risk. Another aspect of the present invention is the administration of bioactive agents via oral fast dispersing/dissolving drug delivery systems for the treatment of dysphagia and/or odynophagia and/or aspiration risk. | 2011-09-29 |
20110237564 | IMIDAZOPYRIMIDINE DERIVATIVES - The invention is concerned with novel imidazopyrimidine derivatives of formula (I) | 2011-09-29 |
20110237565 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE - The present invention relates to compounds and methods which may be useful as inhibitors of H | 2011-09-29 |
20110237566 | Therapeutic Macrolide Compounds and Their Use - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain macrolide compounds (for convenience, collectively referred to herein as “MC compounds”), which, inter alia, are useful in treatment of cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to treat proliferative conditions such as cancer, and in the treatment of diseases and conditions that are mediated by the regulation (e.g. inhibition) of cell proliferation, optionally in combination with another agent. | 2011-09-29 |
20110237567 | TRICYCLIC SPIRO-OXINDOLE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS - This invention is directed to tricyclic spiro-oxindole derivatives of formula (I), wherein j, k, m, n, w, q, Y, Q, X, R | 2011-09-29 |
20110237568 | CRYSTALLINE FORMS - 11-piperazin- | 2011-09-29 |
20110237569 | SPIRO AZEPANE-OXAZOLIDINONES AS Kv1.3 POTASSIUM CHANNEL BLOCKERS - This invention concerns Spiro azepane-ox-azolidinones as voltage gated Kv1.3 potassium channel blockers, pharmaceutical compositions containing these compounds, methods for preparing the compounds, methods for preparing novel intermediates useful for their synthesis, and methods for preparing compositions. The invention also relates to the uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in the treatment of diabetes, psoriasis, obesity, transplant rejection and inflammatory neuropathies, including T-cell mediated autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The compounds have formula (1): | 2011-09-29 |
20110237570 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS - The present invention provides substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutically acceptable salts thereof, and tautomers of any of the foregoing, where such compounds inhibit β-site amyloid precursor protein-cleaving enzyme (BACE), which may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease. The invention also provides pharmaceutical compositions comprising any of these compounds and the use of any of these compounds and compositions in the treatment of diseases, disorders, or conditions in which BACE is involved. | 2011-09-29 |
20110237571 | PHTHALAZINE DERIVATIVES - The present invention relates to novel phthalazine derivatives and, more particularly, to phthalazine derivatives that are useful as protein kinase inhibitors. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and methods of treatment using the compounds. | 2011-09-29 |
20110237572 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives - A compound of Formula I | 2011-09-29 |
20110237573 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS - The present invention relates to compounds of formulae 1 and 2 and methods for modulating the Wnt signaling pathway using these compounds, wherein A | 2011-09-29 |
20110237574 | USE OF MODIFIED PYRIMIDINE COMPOUNDS TO PROMOTE STEM CELL MIGRATION AND PROLIFERATION - This invention provides cells and methods for stimulating proliferation and migration of endogenous and exogenous mammalian stem cells in vivo and in vitro. The invention provides reagents and methods for efficiently proliferating mammalian stem cells in an animal in need thereof and producing stem cells that can be re-introduced into an animal in need thereof to alleviate neurological and corporal disorders. | 2011-09-29 |
20110237575 | INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP) - The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I) | 2011-09-29 |
20110237576 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY - The present invention provides a compound which has an effect of inhibiting amyloid-β production and is useful as a therapeutic agent for diseases induced by production, secretion and/or deposition of amyloid-β proteins. The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: | 2011-09-29 |
20110237577 | BICYCLIC PEPTIDOMIMETIC INHIBITORS OF ASPARTYL-PROTEASES FOR THE TREATMENT OF INFECTIOUS DISEASES - The present invention refers to 3-aza-bicyclo[3.2.1]octane derivatives of general formula (I) their preparation, use and pharmaceutical compositions useful in the treatment of pathologies associated with microbial pathogens expressing aspartyl-protease activity. | 2011-09-29 |
20110237578 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF - Compounds are provided according to formula (I), where A, B, W, X′, L, R | 2011-09-29 |